Abstract
Purpose: The CDK4/6 inhibitors, palbocilib [1] and ribociclib [2,3], have shown significant improvements in progression-free survival (PFS) in ER+/HER2– advanced breast cancers. In the MONALEESA-2 trial, ribociclib showed a significant median overall survival (OS) of 63.9 months [4]. However, in the PALOMA-2 study [5], palbociclib showed a median OS of 53.9 months that was non-significant. The observed differences in OS have generated uncertainty around which CDK4/6 inhibitor to choose in routine clinical practice. In this context, real-world data analysis can be a useful guide to therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
